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Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease accompanied by vascular dysfunction and a tremendous
increaseincardiovascularmortality.Numerousadipose-tissue-derivedfactorsandbetacelldysfunctioncontributetotheincreased
cardiovascular risk in patients with T2DM. Nowadays, numerous pharmacological interventions are available to lower blood
glucose levels in patients with type 2 diabetes. Beside more or less comparable glucose lowering eﬃcacy, some of them have shown
limited or probably even unfavorable eﬀects on the cardiovascular system and overall mortality. Recently, incretin-based therapies
(GLP-1 receptor agonists and DPP-IV inhibitors) have been introduced in the treatment of T2DM. Beside the eﬀects of GLP-1 on
insulinsecretion,glucagonsecretion,andgastrointestinalmotility,recentstudiessuggestedacoupleofdirectcardiovasculareﬀects
of GLP-1-based therapies. The goal of this paper is to provide an overview about the current knowledge of direct GLP-1 eﬀects on
endothelial and vascular function and potential consequences on the cardiovascular outcome in patients with T2DM treated with
GLP-1 receptor agonists or DPP-IV inhibitors.
1.Introduction
The global prevalence of T2DM has been estimated at 171
million people and is projected to more than double by
2030 [1]. The epidemiological establishment of T2DM as
a coronary artery disease equivalent has been conﬁrmed
in several investigations [2–4]. Type 2 diabetes mellitus
(T2DM) is a progressive multisystemic disease accompanied
by endothelial dysfunction [5–7] and an increased cardio-
vascular mortality [3, 8]. Also several mechanistic pathways
linking glucose metabolism with endothelial dysfunction
are postulated; recent studies aimed to investigate the
beneﬁcial role of strict glycemic control using conventional
treatment algorhythms failed to provide beneﬁcial eﬀects
on cardiovascular mortality [9–11]. The accumulation and
interaction of several metabolic and cardiovascular risk
factors merge in the pathophysiology of diabetic vascular
disease and the development of micro- and macrovascular
complications. Diabetic vascular disease has been associated
with an upregulation of reactive oxygen species and chronic
inﬂammatory and hypercoagulable states, and as such with
the pathogenesis of atherosclerosis and cardiovascular dis-
ease.
2.Adipose Tissue,InsulinResistance,and Beta
CellFunction inVascularPathology
Adipose tissue is assumed to play an integral role in the
pathogenesis of vascular dysfunction and the development
of T2DM [12]. As maturing pre-adipocytes diﬀerentiate
to become adult adipocytes, they acquire the ability to
synthesize hundreds of proteins. Adipose tissue releases
a large number of cytokines and bioactive mediators
with endocrine, autocrine, juxtacrine, and paracrine activ-
ity. These proinﬂammatory adipocytokines include TNF-
α, IL-6, leptin, plasminogen activator inhibitor 1 (PAI-
1), angiotensinogen, resistin, and c-reactive protein, all of
them well known to interfere with insulin sensitivity, blood2 Experimental Diabetes Research
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Figure 1: Schematic illustration of the central role of visceral adipose tissue in the generation of the atherogenic environment in
obese patients. Visceral adipose tissue induces insulin resistance, thereby increasing insulin and proinsulin release from the beta cell.
Unphysiological levels of insulin and proinsulin promote atherogenesis through the activation of endothelial MAPK. Preadipocytes secrete
numerousadipocytokinesinvolvedinthepathogenesisofhypertension,dyslipidemia,andinﬂammation.(MAPK:mitogen-activatedprotein
kinase, IL-6: interleukin-6, TNFα: tumor necrosis factor α, FFA: free fatty acids).
pressure regulation, lipid metabolism, and inﬂammation
(Figure 1). On the other hand, the release of adiponectin, an
anti-inﬂammatory and vasoprotective adipokine, is reduced
ininsulin-resistantobesepatientsandinpatientswithT2DM
[13]. In addition, it is likely that many more undiscovered fat
cell-derivedmediatorsarecausallyinvolvedincardiovascular
health, insulin resistance, and the development of T2DM.
Epidemiological evidence suggests that cardiovascular
risk begins to develop many years before the diagnosis
of T2DM [14]. Increasing insulin resistance, associated
with increasing visceral body fat, is associated with an
increased risk for cardiovascular disease and is commonly
comorbid with hypertension, dylipidemia, obesity, and a
prothrombotic state [15–17]. As long as the pancreatic
beta cells compensate for increasing insulin resistance with
an augmented release of insulin, blood glucose will stay
controlled, and the patient will not present, as per deﬁnition,
with frank diabetes mellitus. There are strong prospective
data that, even before deranging glucose levels, obesity
and insulin resistance are associated with atherosclerosis
and coronary heart disease [18, 19]. However, it is the
progressively deteriorating function of the beta cell, which
u l t i m a t e l yl e a d st oh y p e r g l y c e m i aa n di sc r i t i c a lf o rt h e
manifestation of T2DM. There is increasing evidence that
islet cell polymorphisms my account for the individual risk
for beta cell breakdown and the manifestation of T2DM
as deﬁned by an increase in fasting and/or postprandial
blood glucose levels [20, 21]. The insulin/proinsulin ratio
is used as a marker for the capability of the β cell to
convert intact proinsulin into insulin and C-peptide [21].
Preclinical and clinical studies of type 2 diabetes have
identiﬁed proinsulin both as an indicator of decreasing
beta cell function and a predictor of increased beta cell
loss due to apoptosis and/or diminished neogenesis [21,
22]. Furthermore, a direct role of this prohormone in the
development of cardiovascular disease has been suggested
by numerous experimental and epidemiological studies.
Increased intact proinsulin levels were found to be closely
associated with the development of coronary heart disease
involving subjects with and without diabetes [23–27]. In
fact, the atherogenic potential of proinsulin was highlighted
some years ago in a clinical trial, investigating the thera-
peutic potential of human proinsulin given as subcutaneous
injections. In that study, an eightfold increase in cardiovas-
cular events was observed during treatment with human
proinsulin versus human regular insulin [28]. More recently,
an association between increased plasma concentrations of
proinsulin and the severity of angiographically characterized
coronaryheartdiseasehasbeenreported[29].Eventheexact
mechanism how proinsulin is involved in the pathogenesis
of atherosclerosis is not completely recognized, it was
already shown that PAI-1 activity increases after proinsulin
administration in vitro [30]. Increased expression of PAI-
1 and vascular adhesion molecules have been associated
with hyperglycemia-related endothelial cell dysfunction and
a predisposition to accelerated atherogenesis [31]. There is
increasing evidence that the atherogenic eﬀects of proinsulin
might, at least in part, be mediated by increasing PAI-
1 levels with subsequent inhibition of ﬁbrinolysis and an
augmented thrombogenic potency [32–34]. In accordance
with this ﬁnding, the reduction of intact proinsulin levels
during treatment with a PPARγ agonist in T2DM was shownExperimental Diabetes Research 3
to be associated with a decrease in intima media thickness of
the arteria carotis communis [35].
3.EndothelialDysfunctioninDiabetesMellitus
Vascular wall dysfunction is a critical mediator of athero-
genesis in patients with T2DM. The response to injury
hypotheses of atherosclerosis supposed that the initial dam-
age aﬀects the arterial endothelium leading to endothelial
dysfunction [36]. Endothelial dysfunction in patients with
obesity and T2DM is characterized by an imbalance between
endothelium-dependent vasodilatation and vasoconstriction
as well as antithrombotic and prothrombotic factors. Nitric
oxide (NO) maintains the vasodilatation and vasoprotective
property of the endothelium and opposes the eﬀects of
vasoconstrictors such as endothelin 1 or angiotensin II [6,
37]. It inhibits leucocyte and platelet activation and helps
to maintain the endothelium as smooth nonthrombotic
barrier. Thus endothelial dysfunction is a prominent feature
at various stages of atherogenesis, vessel occlusion, and tissue
infarction [12]. In a study by Goldﬁne et al., endothelial
function and NO bioavailability was evaluated in 38 indi-
viduals without a history of T2DM [38]. In this study, 19
patients were oﬀspring of type 2 diabetes parents, while the
other 19 had no ﬁrst degree relatives with either T2DM
or cardiovascular disease. Patients with a family history of
diabetes were found to have signiﬁcantly reduced endothelial
function and nitric oxide (NO) bioavailability.
Beside the well-known metabolic eﬀects of insulin, the
hormone exerts important vascular eﬀects through the
activation of opposing intracellular signaling pathways.
Under normal conditions, insulin provides vasodilatation
and vasoprotective eﬀects through the activation of the
Phosphoinositol-3-Kinase pathway (PI-3K) and promoting
the release of NO. In contrast, in case of insulin resistance
andanunphysiologicalreleaseofinsulinandproinsulinfrom
the beta cells, the signal shifts from the vasoprotective PI-
3K pathway to the mitogen activated proteinkinase (MAPK)
pathway (Figure 2). In this case, the vasodilating and beneﬁ-
cial eﬀects of insulin turn over into the vasoconstrictive and
mitogenic properties of insulin [6, 39].
4. Effects of GLP-1on Body Weightand
BetaCellFunction
Nowadays, numerous pharmacological interventions are
available to lower blood glucose levels in patients with type 2
diabetes. Beside more or less comparable glucose lowering
eﬃcacy, some of them have shown limited or probably
even unfavorable eﬀects on the cardiovascular system and
overall mortality [40–44]. Therefore, treatments in T2DM
should be reevaluated not solely by judging their glucose
lowering potency, but, moreover, on their overall eﬀects
on the cardiovascular risk proﬁle and overall mortality in
patients with T2DM.
Recently, incretin-based therapies have been introduced
in the treatment of T2DM. Incretins, gut-derived hormones,
predominantly glucagon peptide 1 (GLP-1), and gastric
inhibitory polypeptide (GIP), are released in response to an
ingested meal. They reduce blood glucose concentrations
by enhancing the insulin release from pancreatic beta cells
[45] and inhibiting postprandial glucagon secretion [46,
47] and gastric emptying after a meal [48]. However, only
GLP-1 seemed to be suitable for the treatment of type 2
diabetic patients since the action of GIP was found to be
grossly impaired in patients with T2DM [49]. Following its
release from the L-cells into the blood stream, GLP-1 [7–
36] is quickly cleaved by the enzyme dipeptidyl-peptidase-
IV (DPP-IV) into the split product GLP-1 [9–39], which
results in a half-life time of GLP-1 [7–39] of only 2 min-
utes. Therefore, strategies have been developed to increase
the therapeutical window of GLP-1-based treatments by
inhibiting the degrading enzyme DPP-IV or by providing
exogenous agonists of GLP-1, which are resistant to the
degradation by DPP-IV. At present, four DPP-IV inhibitors
(Sitagliptin, Vildagliptin, Saxagliptin, and Linagliptin) and
two GLP-1 receptor agonists (Exenatide and Liraglutide) are
approved for the treatment of T2DM. In several studies,
treatment with DPP-IV inhibitors and GLP-1 receptor
agonists was shown to improve blood glucose control in
type 2 diabetic patients without increasing the risk of
hypoglycemia. While treatment with DPP-IV inhibitors was
shown to be more or less weight neutral, treatment with the
GLP-1receptoragonistsreducedbody weightin themajority
of patients with T2DM [50]. Beside these overall weight
reducing eﬀects of GLP-1 receptor agonists a pronounced
reduction in visceral body fat was shown during treatment
with Liraglutide [51]. In another study, treatment with the
GLP-1 receptor agonist Exenatide resulted in a reduction in
body weight, waist circumference, total body, and truncal
fat mass by 6%, 5%, 11%, and 13%, respectively [52]. In
addition, exenatide increased total adiponectin by 12% and
reduced high-sensitive CRP by 61%. Treatment with GLP-
1 receptor agonists has been consistently demonstrated to
reduce blood pressure, as observed in clinical trials with
exenatide or liraglutide [53–57]. Of interest is, that the
reduction of blood pressure in most studies occurred even
before weight reduction could be achieved, indicating direct
eﬀects of GLP-1 on blood pressure. The mechanisms beyond
the blood pressure lowering eﬀects of GLP-1 are still unclear.
Beside changes in the release of adipokines from the adipose
tissue, direct vasodilatory eﬀects [58] and renal natriuretic
eﬀects [59] of GLP-1 might cause the beneﬁcial eﬀects of
GLP-1 on blood pressure.
Recently, it has been reported that the vulnerability
of the beta cell to release the prohormone intact proin-
sulin, instead of insulin and C-peptide, is linked to beta
cell polymorphisms observed in three diﬀerent risk alleles
[22]. The mechanisms by which these risk alleles (HHEX,
CDKN2A/B, and IGF2BP2) inﬂuence proinsulin processing
are still a matter of debate. Loos et al. demonstrated that
the genes of pro-protein convertases 1 and 2, which are
key proteins in the conversion from proinsulin to insulin,
exhibit binding sites for the T-cell transcription factor [60].
Therefore, an interaction with these pro-protein convertases
may be a mechanism leading to increased proinsulin levels
in carriers of the risk alleles [22]. As GLP-1 infusion4 Experimental Diabetes Research
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Figure 2: Schematic illustration of intracellular insulin signalling (aPKC: atypical Protein-Kinase C, eNOS: endothelial Nitric Oxide
Synthase, ET1: Endothelin 1, FOX01: Forkhead Box01, IRS: Insulin Receptor Substrate, MAPK: Mitogen Activated Proteinkinase, MEK:
Mitogen Activated Proteinkinase Kinase, NO: Nitric Oxide, PDK: Phosphoinositide-Dependent Kinase, PI3K: Phosphatidylinostol 3 Kinase,
RAS, RAF: Proto-Oncogenes, SHC: Adapter Protein; adapted to [6]).
is able to normalize reduced proinsulin conversion, and
GLP-1 signaling is impaired in carriers of the risk alleles
in TCF7L2, it is conceivable that an attenuated GLP-1
signaling might lead to an impaired proinsulin processing
[61]. Several clinical studies have shown an improvement in
the Proinsulin/Insulin Ratio during treatment with GLP-1
receptor agonists [62, 63] and DPP-IV inhibitors [64–66]. In
a cross-sectional study, postprandial intact proinsulin levels
were signiﬁcantly higher in sulfonylurea-treated patients
compared to insulin and DPP-IV-inhibitor-treated patients
and a non-diabetic control group [67]. As shown in Figure 3,
the proinsulin/insulin ratio was comparable in between the
DPP-IV-inhibitor-treated group and the nondiabetic control
group, while it was evaluated in the sulfonylurea- and the
insulin-treated group. In a recent study, the introduction
of liraglutide treatment caused a pronounced decrease in
intact proinsulin levels, which was found in parallel with
a reduction in E-Selectin, asymmetric-dimethyl-arginine
(ADMA), and PAI-1 levels, and an improvement in endothe-
lial function [68]. Therefore, it seems conceivable that GLP-
1-based treatments do not only improve beta cell function
by an induction of the proinsulin convertases but also
reduce vascular risk by the reduction in circulating absolute
proinsulin levels.
5. Effects of GLP-1on Endothelial
andCardiovascularFunction
GLP-1 acts through a distinct heptahelical G-protein-
coupled receptor, which has been located not only in beta
cells and the gastrointestinal tract, but also in the nervous
system, heart, vascular smooth muscle cells, endothelial
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Figure 3: Postprandial proinsulin/insulin ratio in patients treated
withsulfonylurea,insulinGlargine, orDPP-IVinhibitorscompared
to nondiabetic healthy controls (∗: P<0.05 versus nondiabetic
controls adapted to [67]).
cells, and macrophages [45, 58, 70, 71]. GLP-1 appears to
modulate a wide range of physiological eﬀects, not only
regulating blood glucose and metabolic control, but also
directly aﬀecting several cardiovascular pathways involved in
atherogenesis. Binding of GLP-1 to the GLP-1 receptor in
the myocardium leads to an increase in the production of
cyclic adenosine monophosphate (cAMP) and an activation
of protein kinase A (PKA), which results in an increase in
glucose uptake and the inotropic eﬀects in myocardial tissue.
GLP-1 knockout mice exhibit reduced resting heart rate,
elevated left ventricular and diastolic pressure, and increased
left ventricular thickness compared with normal controlsExperimental Diabetes Research 5
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Figure 4: Schematic illustration of GLP-1-receptor-dependent and GLP-1-receptor-independent pathways in the signalling of GLP-1
associated cardiovascular eﬀects (PI3K: phosphatidylinositol 3 kinase; cAMP: cyclic adenosine monophosphate, PKA: protein kinase A,
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[58]. In agreement with this ﬁndings, treatment with GLP-
1 or the GLP-1 receptor agonists was found to improve
left ventricular function [72, 73] and to reduce circulating
levels of brain natriuretic peptide (BNP) [74, 75]. GLP-1
increased functional cardiomyocyte viability in an isolated
mouse heart reperfusion model but, unexpectedly, many of
these actions were preserved in the GLP-1 knockout mouse
model,suggestingcardiovasculareﬀectsthatareindependent
of the GLP-1-receptor-mediated activation of cAMP/PKA
[50]. Ban et al. studied the myocardial eﬀects of GLP-1 (7-
39) and GLP-1(9-39) under postischemic conditions in both
wild-typeandGLP1r(−/−)(GLP-1receptorknockoutmice)
[58]. In wild-type mice, some of the eﬀects of GLP-1 (7-
3 9 )c o u l db er e p r o d u c e db yt h et r u n c a t e dp e p t i d eG L P - 1( 9 -
39). Those eﬀects could also be induced by GLP1 (7-39) and
GLP-1 (9-39) in the GLP1r(−/−) knockout mouse model.
In addition, the beneﬁcial eﬀects of GLP-1 in the knockout
mouse model could be abolished by the addition of the DPP-
IVinhibitorSitagliptin andbytheadministration oftheNO-
synthase blocker L-NNA (NG-nitro-arginine). This leads to
the hypothesis of a two pathway mechanism for the protec-
tive cardiovascular action of GLP-1. One that depends on
the GLP-1 receptor mediated action with inotropic, glucose
uptake stimulating, ischemic preconditioning eﬀects, and
one, receptor independent vasodilatatory pathway, which is
mediated by NO (Figure 4).
Growing lines of evidence demonstrate beneﬁcial eﬀects
of GLP-1 on endothelium and vascular smooth muscle
cells [58, 76–78]. In human vascular endothelial cells,
liraglutide caused eNOS phosphorylation and potentiated
eNOSactivitywithanincreasednitricoxideproduction[79].
In endothelial cells, isolated from human coronary arteries,
GLP-1 rapidly activates endothelial nitric oxide synthase
(eNOS), promotes cell proliferation, and inhibits glucol-
ipoapoptosis [80]. In healthy, nondiabetic, subjects, GLP-
1 infusion enhanced the acetylcholine-mediated increase
in forearm blood ﬂow, while no such eﬀect could be
observed on endothelial-independent vasodilatation after
sodium nitroprusside [78]. Interestingly, in that study, the
beneﬁcial eﬀects of GLP-1 on endothelial function were
damped by the addition of glyburide, but not by glimepiride.
In type 2 diabetic patient with coronary artery disease,
infusion of GLP-1 increased ﬂow-mediated vasodilatation in
the brachial artery, aﬃrming the NO-dependent mechanism
of GLP-1 in the vascular system [81]. In this study, no such
eﬀect could be observed in nondiabetic healthy controls.
6.Other PotentialCardiovascularBeneﬁts
Treatment with the GLP-1 receptor agonists, liraglutide and
exenatide, was shown to reduce PAI-1 levels in patients
with T2DM [68, 74, 75, 82]. In cultured human vascular
endothelial cells, Liraglutide inhibited the expression of
tumor necrosis factor-α (TNF α) and the hyperglycemia-
mediated induction of VCAM-1 and PAI-1 [74, 80]. This
may be of relevance as elevated PAI-1 levels have been
implicated in endothelial cell dysfunction [83]. In a previous
study, 14 weeks of treatment with liraglutide signiﬁcantly
decreased PAI-1 levels by 25% [74]. Complementing the6 Experimental Diabetes Research
beneﬁcial eﬀect on PAI-1 levels, liraglutide attenuates the
induction of PAI-1 and vascular adhesion molecules in vitro
[31].
A recent metaanalysis of the 6 trials from the LEAD
program revealed that treatment with the GLP-1 receptor
agonist liraglutide decreased hsCRP levels by 23% from
baseline till 6 months [84]. In a study comparing exe-
natide and glargine treatment, treatment with exenatide
over a period of 12 months reduces hsCRP levels by 61%
[52].
In addition to the eﬀects on myocardium and the
endothelial cells, GLP-1 may also have eﬀects on athero-
genesis through direct interactions with monocytes or
macrophages. Treatment with Exenatide signiﬁcantly inhib-
ited monocyte adhesion in the aorta of C57BL/6 mice [85].
In apoE(−/−) mice, the same treatment reduced monocyte
adhesion to the endothelium and suppressed atherogenesis.
As pointed out by Zilversmit many years ago, atheroscle-
rosis could be considered to be a prandial phenomenon
[86]. Therefore, GLP-1 might serve as a metabolic and
vasoprotective factor evolving its main eﬀects after the
ingestion of a meal. In a study by Koska et al. postprandial
endothelial function was investigated in IGT subjects and in
patients with recently diagnosed T2DM by reactive hyper-
emia peripheral arterial tonometry [87]. In that study, a sin-
gle dose of Exenatide resulted in a signiﬁcant improvement
in postprandial endothelial function compared with placebo
administration. In another study, intravenous GLP (7-39)
infusion resulted in a signiﬁcant improvement of postpran-
dial FMD during an OGT and during a hyperglycemic clamp
procedure [88]. The improvement in FMD was paralleled
by a reduced postprandial increase in nitrotyrosine and 8-
iso-PGF2a levels. These results suggest that GLP-1 has the
potential to reduce glucose load, oxidative stress and to
improve endothelial function especially in the postprandial
state.
How far all the previously observed pleiotropic eﬀects
of GLP-1 will translate in a reduction of micro- and/or
macrovascular complications in patients with T2DM is still
not established. In a retrospective analysis of the LifeLink
database, patients treated with the GLP-1 receptor agonist
Exenatide were less likely to have a CVD event (HR 0.81,
P = 0.01) and lower rates of CVD-related hospitalization
(HR 0.88, P = 0.02) [89]. A recent meta-analysis assessing
the cardiovascular outcome of GLP-1-receptor agonists in
clinical trials up to November 2010 revealed a signiﬁcant
lower rate of major cardiovascular events in GLP-1-receptor-
agonist-treated patients compared to placebo [90]. Ongoing
randomized prospective clinical studies will provide more
evidence about potential clinical long-term eﬀects of GLP-
receptor agonist or DPP-IV inhibitor treatment in patients
with T2DM at cardiovascular risk.
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